## Redx Pharma Plc

- Redx AI division established April 2013 at Alderley Park
- Sixty research scientists (microbiologists, DMPK, computational and medicinal chemistry)
- Focus on overcoming existing anti-microbial resistance mechanisms:
- Gram +ve program: Development candidate selected
- Gram -ve program: Lead optimisation
- Work collaboratively with academics, the NHS, BEAM alliance, large pharma and ENABLE
- Open to partnerships; Happy to discuss at BIO
- M.craighead@redxpharma.com
- www.redxpharma.com


## Red® Pharma

## Gram negative program overview

- Three series of novel, non-quinolone, inhibitors of the bacterial type II topoisomerases, DNA gyrase and topoisomerase IV
- Potent compounds with broad/ narrow spectrum of activity against resistant strains including recent clinical isolates
- Low frequency of resistance with balanced activity at both target enzymes
- PK properties suitable for iv dosing



## Gram positive program overview

- Development candidate selected
- Inhibit bacterial DNA Gyrase without chelating $\mathrm{Mg}^{2+}$ - by-pass resistance observed with FQ antibiotics
- X-ray studies confirm differential binding from quinolones
- Broad spectrum of activity including resistant strains (S. aureus, S. epidermidis \& S. pyogenes)
- Excellent activity in mouse thigh, septicaemia \& N. gonorrhoeae models


## Red® Pharma



